Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
By Dominic Chopping
Novo Nordisk agreed to pay up to $1.3 billion to license and develop Swedish pharmaceutical company Nanexa's drug delivery technology in a deal that could cut the frequency that patients need to inject its obesity and diabetes drugs.
The deal covers Nanexa's PharmaShell technology, which is designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin coating applied to individual drug particles.
Under the exclusive deal announced late Thursday, Novo has licensed Nanexa's technology in up to five development programs covering different drug administration frequencies, with the companies targeting monthly and quarterly administration.
Novo will lead global development and commercialization, with Nanexa eligible to receive upfront consideration and potential milestone payments totaling up to 1.17 billion euros ($1.33 billion).
The Danish drugmaker will pay 615 million euros in upfront and development and regulatory milestone payments, in addition to royalties on future product sales.
Nanexa shares more than doubled on the news in early Stockholm trade, rising to as much as 15.50 kronor from Thursday's closing price of 5.93 kronor.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 25, 2026 04:34 ET (08:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States